Work

Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting

Year: 2020

Type: article

Abstract: Within ten years after breast cancer diagnosis, 5% of patients develop contralateral primary breast cancer (CBC). Randomized trials have found that tamoxifen and aromatase inhibitors (AIs) reduce CBC risk. However, little is known about the magnitude and duration of protective effects within the context of “real world” clinical management settings, where varying durations and gaps in treatment are common.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/6kc2-9x38

Authors: Glass, Andrew G., Nyante, Sarah J., Ntowe, Estelle A., Gierach, Gretchen L., Feigelson, Heather Spencer, Mullooly, Maeve, Hoover, Robert N., Pfeiffer, Ruth M., Curtis, Rochelle E., De Gonzalez, Amy Berrington

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Multiple and Secondary Primary Cancers

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4297926379

FWCI:

Cites:

Cited by:

Related to: 10